1
Hinton Paul R, Tsurushita Naoya, Tso J Yun, Vasquez Maximiliano: Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis. Protein Design Labs, Hinton Paul R, Tsurushita Naoya, Tso J Yun, Vasquez Maximiliano, LIEBESCHUETZ Joe, October 28, 2004: WO/2004/092219 (75 worldwide citation)

The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the un ...


2
Hinton Paul R, Tsurushita Naoya, Tso Yun J, Vasquez Maximiliano: Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis. Protein Design Labs, Hinton Paul R, Tsurushita Naoya, Tso Yun J, Vasquez Maximiliano, LIEBESCHUETZ Joe, December 29, 2005: WO/2005/123780 (62 worldwide citation)

The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the un ...


3
Hinton Paul R, Tsurushita Naoya: Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig. Pdl Biopharma, Hinton Paul R, Tsurushita Naoya, LIEBESCHUETZ JOE, April 28, 2005: WO/2005/037867 (56 worldwide citation)

The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodif ...


4
Chilcote Tamie, Barbour Robin: Antibodies to alpha-synuclein. Elan Pharmaceuticals, Chilcote Tamie, Barbour Robin, LIEBESCHUETZ Joe, May 26, 2005: WO/2005/047860 (35 worldwide citation)

The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.


5
Chilcote Tamie J, Goldstein Jason, Anderson John P, Walker Donald: Truncated fragments of alpha-synuclein in lewy body disease. Elan Pharmaceuticals, Chilcote Tamie J, Goldstein Jason, Anderson John P, Walker Donald, LIEBESCHUETZ Joe, April 27, 2006: WO/2006/045037 (21 worldwide citation)

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fr ...


6
Beraud Christophe, Mirza Amer Mushtaq: Sirna libraries. Cytokinetics, Beraud Christophe, Mirza Amer Mushtaq, LIEBESCHUETZ Joe, December 16, 2004: WO/2004/108897 (19 worldwide citation)

The invention provides methods of expressing an siRNA starting from a single template encoding one strand of the siRNA. The methods are particularly suitable for generating large libraries of random siRNAs in which one strand of each siRNA can be synthesized simultaneously in a solid-phase synthesis ...


7
Kim Kyung Jin, Su Yi Chi: Monoclonal antibodies to hepatocyte growth factor. Kim Kyung Jin, Su Yi Chi, Galaxy Biotech, LIEBESCHUETZ Joe, November 17, 2005: WO/2005/107800 (18 worldwide citation)

The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient, such as for inhibiting glioblastoma.


8
Kim Kyung Jin, Laterra John, Lal Bachchu: Methods of treating brain tumors with antibodies. Galaxy Biotech, Kennedy Krieger Institute, Johns Hopkins University, Kim Kyung Jin, Laterra John, Lal Bachchu, LIEBESCHUETZ Joe, December 7, 2006: WO/2006/130773 (14 worldwide citation)

The application is directed toward a method of treating a brain tumor in a patient comprising systemically administering a monoclonal antibody.


9
Chilcote Tamie J, Goldstein Jason, Anderson John P: Truncated fragments of alpha-synuclein in lewy body disease. Elan Pharmaceuticals, Chilcote Tamie J, Goldstein Jason, Anderson John P, LIEBESCHUETZ Joe, February 17, 2005: WO/2005/013889 (14 worldwide citation)

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fr ...


10
Kim Kyung Jin, Wang Lihong, Park Hangil, Vasquez Maximiliano: Humanized monoclonal antibodies to hepatocyte growth factor. Galaxy Biotech, Kim Kyung Jin, Wang Lihong, Park Hangil, Vasquez Maximiliano, LIEBESCHUETZ Joe, October 11, 2007: WO/2007/115049 (13 worldwide citation)

The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.